Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Eur J Cancer Prev ; 25(6): 518-23, 2016 11.
Article in English | MEDLINE | ID: mdl-26633164

ABSTRACT

Prostate-specific antigen blood testing has improved early detection of prostate cancer (PCa); however, PCa mortality has not decreased accordingly and a prostate biopsy is still required for a definitive diagnosis. Proteomic biomarker screening in easily available body fluids such as seminal plasma is now increasingly being proposed as a solution to improve PCa detection and prognosis. PCa cells typically produce high levels of reactive oxygen species (ROS). In this study, we therefore investigated ROS levels in semen samples from patients with a negative or a positive prostate biopsy to predict PCa diagnosis. Multiple clinicopathological parameters (digital rectal examination, prostate-specific antigen scoring, prostate biopsy, and ROS levels) of patients examined for PCa were measured. No significant differences in ROS levels were detected in relation to PCa diagnosis. Although seminal plasma is a well-suited medium for prostate-related biomarkers, no significant differences in ROS levels were observed between the patient groups. Comparison with ROS levels encountered in semen of larger patient groups is the next logical step.


Subject(s)
Biomarkers, Tumor/metabolism , Oxidative Stress , Prostatic Neoplasms/diagnosis , Reactive Oxygen Species/metabolism , Semen/metabolism , Aged , Female , Humans , Male , Middle Aged , Prognosis , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...